Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup

Jean Schmidt, Tanaz A. Kermani, A. Kirstin Bacani, Cynthia Crowson, Eric Lawrence Matteson, Kenneth J Warrington

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Objective. To report a single-center experience with the use of tumor necrosis factor (TNF) inhibitors in patients with Takayasu arteritis (TA). Methods. We retrospectively studied a cohort of patients with refractory TA evaluated at our institution and treated with TNF inhibitors. American College of Rheumatology criteria for TA were used for inclusion. Disease activity was assessed according to the National Institutes of Health criteria. Results. We included 20 patients (19 women, 17 white) with a mean ± SD age of 33 ± 10.2 years and a median disease duration of 15.9 months (interquartile range [IRQ] 2-32.7 months) prior to the use of TNF inhibitors. Before the use of TNF inhibitors, all 20 patients received prednisone. Other medication use included methotrexate (18 patients), azathioprine (5 patients), mycophenolate mofetil (3 patients), and cyclophosphamide (3 patients). Seventeen patients (85%) received infliximab, 2 patients (10%) received adalimumab, and 1 patient (5%) received etanercept. The median duration of treatment with TNF inhibitors was 23.0 months (IQR 8.7-38.9 months). Treatment with TNF inhibitors resulted in disease remission in 18 (90%) of 20 patients and sustained remission in 10 patients (50%). Ten (83%) of 12 patients were able to taper prednisone below 10 mg and 7 patients discontinued prednisone. However, 6 of the 18 patients achieving remission experienced relapse while receiving TNF inhibitors. Eleven patients (55%) discontinued TNF inhibitors for the following reasons: relapse, persistently active disease, lack of corticosteroid-sparing effect, adverse effects (4 patients), and other reasons (4 patients). Conclusion. In this study, treatment with TNF inhibitors induced remission, including sustained remission in patients with refractory TA. However, 33% of patients experienced disease relapse while receiving TNF inhibitors and 20% discontinued treatment because of adverse events.

Original languageEnglish (US)
Pages (from-to)1079-1083
Number of pages5
JournalArthritis Care and Research
Volume64
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Takayasu Arteritis
Referral and Consultation
Tumor Necrosis Factor-alpha
Prednisone
Recurrence
Mycophenolic Acid

ASJC Scopus subject areas

  • Rheumatology

Cite this

Tumor necrosis factor inhibitors in patients with Takayasu arteritis : Experience from a referral center with long-term followup. / Schmidt, Jean; Kermani, Tanaz A.; Bacani, A. Kirstin; Crowson, Cynthia; Matteson, Eric Lawrence; Warrington, Kenneth J.

In: Arthritis Care and Research, Vol. 64, No. 7, 07.2012, p. 1079-1083.

Research output: Contribution to journalArticle

@article{06edbbe3ad464dffa3e8cf0ded35bb86,
title = "Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup",
abstract = "Objective. To report a single-center experience with the use of tumor necrosis factor (TNF) inhibitors in patients with Takayasu arteritis (TA). Methods. We retrospectively studied a cohort of patients with refractory TA evaluated at our institution and treated with TNF inhibitors. American College of Rheumatology criteria for TA were used for inclusion. Disease activity was assessed according to the National Institutes of Health criteria. Results. We included 20 patients (19 women, 17 white) with a mean ± SD age of 33 ± 10.2 years and a median disease duration of 15.9 months (interquartile range [IRQ] 2-32.7 months) prior to the use of TNF inhibitors. Before the use of TNF inhibitors, all 20 patients received prednisone. Other medication use included methotrexate (18 patients), azathioprine (5 patients), mycophenolate mofetil (3 patients), and cyclophosphamide (3 patients). Seventeen patients (85{\%}) received infliximab, 2 patients (10{\%}) received adalimumab, and 1 patient (5{\%}) received etanercept. The median duration of treatment with TNF inhibitors was 23.0 months (IQR 8.7-38.9 months). Treatment with TNF inhibitors resulted in disease remission in 18 (90{\%}) of 20 patients and sustained remission in 10 patients (50{\%}). Ten (83{\%}) of 12 patients were able to taper prednisone below 10 mg and 7 patients discontinued prednisone. However, 6 of the 18 patients achieving remission experienced relapse while receiving TNF inhibitors. Eleven patients (55{\%}) discontinued TNF inhibitors for the following reasons: relapse, persistently active disease, lack of corticosteroid-sparing effect, adverse effects (4 patients), and other reasons (4 patients). Conclusion. In this study, treatment with TNF inhibitors induced remission, including sustained remission in patients with refractory TA. However, 33{\%} of patients experienced disease relapse while receiving TNF inhibitors and 20{\%} discontinued treatment because of adverse events.",
author = "Jean Schmidt and Kermani, {Tanaz A.} and Bacani, {A. Kirstin} and Cynthia Crowson and Matteson, {Eric Lawrence} and Warrington, {Kenneth J}",
year = "2012",
month = "7",
doi = "10.1002/acr.21636",
language = "English (US)",
volume = "64",
pages = "1079--1083",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Tumor necrosis factor inhibitors in patients with Takayasu arteritis

T2 - Experience from a referral center with long-term followup

AU - Schmidt, Jean

AU - Kermani, Tanaz A.

AU - Bacani, A. Kirstin

AU - Crowson, Cynthia

AU - Matteson, Eric Lawrence

AU - Warrington, Kenneth J

PY - 2012/7

Y1 - 2012/7

N2 - Objective. To report a single-center experience with the use of tumor necrosis factor (TNF) inhibitors in patients with Takayasu arteritis (TA). Methods. We retrospectively studied a cohort of patients with refractory TA evaluated at our institution and treated with TNF inhibitors. American College of Rheumatology criteria for TA were used for inclusion. Disease activity was assessed according to the National Institutes of Health criteria. Results. We included 20 patients (19 women, 17 white) with a mean ± SD age of 33 ± 10.2 years and a median disease duration of 15.9 months (interquartile range [IRQ] 2-32.7 months) prior to the use of TNF inhibitors. Before the use of TNF inhibitors, all 20 patients received prednisone. Other medication use included methotrexate (18 patients), azathioprine (5 patients), mycophenolate mofetil (3 patients), and cyclophosphamide (3 patients). Seventeen patients (85%) received infliximab, 2 patients (10%) received adalimumab, and 1 patient (5%) received etanercept. The median duration of treatment with TNF inhibitors was 23.0 months (IQR 8.7-38.9 months). Treatment with TNF inhibitors resulted in disease remission in 18 (90%) of 20 patients and sustained remission in 10 patients (50%). Ten (83%) of 12 patients were able to taper prednisone below 10 mg and 7 patients discontinued prednisone. However, 6 of the 18 patients achieving remission experienced relapse while receiving TNF inhibitors. Eleven patients (55%) discontinued TNF inhibitors for the following reasons: relapse, persistently active disease, lack of corticosteroid-sparing effect, adverse effects (4 patients), and other reasons (4 patients). Conclusion. In this study, treatment with TNF inhibitors induced remission, including sustained remission in patients with refractory TA. However, 33% of patients experienced disease relapse while receiving TNF inhibitors and 20% discontinued treatment because of adverse events.

AB - Objective. To report a single-center experience with the use of tumor necrosis factor (TNF) inhibitors in patients with Takayasu arteritis (TA). Methods. We retrospectively studied a cohort of patients with refractory TA evaluated at our institution and treated with TNF inhibitors. American College of Rheumatology criteria for TA were used for inclusion. Disease activity was assessed according to the National Institutes of Health criteria. Results. We included 20 patients (19 women, 17 white) with a mean ± SD age of 33 ± 10.2 years and a median disease duration of 15.9 months (interquartile range [IRQ] 2-32.7 months) prior to the use of TNF inhibitors. Before the use of TNF inhibitors, all 20 patients received prednisone. Other medication use included methotrexate (18 patients), azathioprine (5 patients), mycophenolate mofetil (3 patients), and cyclophosphamide (3 patients). Seventeen patients (85%) received infliximab, 2 patients (10%) received adalimumab, and 1 patient (5%) received etanercept. The median duration of treatment with TNF inhibitors was 23.0 months (IQR 8.7-38.9 months). Treatment with TNF inhibitors resulted in disease remission in 18 (90%) of 20 patients and sustained remission in 10 patients (50%). Ten (83%) of 12 patients were able to taper prednisone below 10 mg and 7 patients discontinued prednisone. However, 6 of the 18 patients achieving remission experienced relapse while receiving TNF inhibitors. Eleven patients (55%) discontinued TNF inhibitors for the following reasons: relapse, persistently active disease, lack of corticosteroid-sparing effect, adverse effects (4 patients), and other reasons (4 patients). Conclusion. In this study, treatment with TNF inhibitors induced remission, including sustained remission in patients with refractory TA. However, 33% of patients experienced disease relapse while receiving TNF inhibitors and 20% discontinued treatment because of adverse events.

UR - http://www.scopus.com/inward/record.url?scp=84863484853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863484853&partnerID=8YFLogxK

U2 - 10.1002/acr.21636

DO - 10.1002/acr.21636

M3 - Article

C2 - 22328491

AN - SCOPUS:84863484853

VL - 64

SP - 1079

EP - 1083

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 7

ER -